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Abstract
It is recognised that stromal cells determine cancer progression. We have previously shown that active TGFb
produced by rat colon carcinoma cells modulated NO production in rat endothelial cells. To elucidate the role of
TGFb and NO in the mechanisms of interaction of colon carcinoma cells with stromal cells and in cancer pro-
gression, we transfected REGb cells, a regressive colon carcinoma clone secreting latent TGFb, with a cDNA
encoding for a constitutively-secreted active TGFb. Out of 20 injected rats only one tumour progressed, which was
resected and sub-cultured (ReBeta cells). ReBeta cells secreted high levels of active TGFb. The adhesive properties
of REGb and Rebeta cells to endothelial cells were similar, showing that the secretion of active TGFb is not
involved in tumour cell adhesion to endothelial cells. ReBeta, but not REGb, cell culture supernatants inhibited
cytokine-dependent NO secretion by endothelial cells, but inhibition of NO production was similar in co-cultures of
REGb or ReBeta cells with endothelial cells. Therefore, secretion of active TGFb regulated endothelial NO syn-
thase activity when tumour cells were distant from, but not in direct contact with, endothelial cells. However, only
ReBeta cells inhibited cytokine-dependent secretion of NO in coculture with macrophages, indicating that the
active-TGFb–NO axis confers an advantage for tumour cells in their interaction with macrophages rather than
endothelial cells in cancer progression.
Abbreviations: BMDM – bone marrow-derived macrophages; CM – conditioned medium; DMEM – dulbecco’s
modiﬁed Eagle’s medium; ELISA – enzyme-linked immunosorbent assay; FCS – fetal calf serum; IFN-c – interferon
gamma; IL1b – interleukin-1beta; LPS – lippopolysaccharide; MMP – matrix metalloprotease; NO – nitric oxide;
NOS – nitric oxide synthase; PBS – phosphate buﬀered saline; SD – standard deviation; TNF-a – tumour necrosis
factor-alpha; TGFb – transforming growth factor-beta
Introduction
To progress and successfully metastasise tumour cells
have to resist defence mechanisms of the host organ
stromal cells. Nitric oxide (NO) derived from macro-
phages and endothelial cells has been shown to reduce
adhesion of tumour cells to endothelial cells and par-
ticipates in tumouricidal activity against many types of
tumours [1–8]. Cells, including macrophages and endo-
thelial cells, express an inducible form of NO synthase
(iNOS) [9] which has been involved in defence mecha-
nisms against pathogens and tumour cells. Conse-
quently, the capacity of tumour cells to modulate the
level of NO production at the metastasis site could be
crucial in regulating adhesive properties and survival of
tumour cells and may determine the outcome of cancer
metastasis.
TGFb has been involved in the mechanisms regu-
lating tumour progression. However, the function of
TGFb in cancer depends on the tumour stage and
context [10]. In early stages TGFb is anti-tumoural,
inhibiting proliferation of tumour cells, whereas in later
stages, TGFb signalling pathways in tumour cells are
inactivated. TGFb then promotes cancer progression,
acting as a permissive factor for stromal cells, inhibiting
host immune surveillance, stimulating invasion, angio-
genesis and metastasis. TGFb also regulates protease
secretion, including matrix metalloproteases (MMPs),
or tumour cell interaction with endothelial cells [11–13].
We have previously shown that a progressive clone
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(PROb cells) of a chemically-induced rat colon carci-
noma, secreting active TGFb inhibited NO synthase
induction and NO secretion in rat EC219 endothelial
cells, whereas a regressive clone (REGb cells) isolated
from the same colon carcinoma, secreting only latent
TGFb did not regulate NO production by EC219 cells
[14]. In order to elucidate the role of tumour cell-derived
TGFb in the TGFb–NO axis in cancer progression, we
transfected REGb cells with a constitutively-secreted
active form of TGFb and evaluated the potential for
these cells to form progressive tumours in vivo in tu-
mour-cells syngeneic rats and to interact in vitro either
with endothelial cells or macrophages expressing func-
tional TGFb receptors.
Materials and methods
Cell lines
The development and characterisation of the rat EC219
endothelial cell line have been described [15]. Cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
1 g/l glucose; Life Technologies, Basel, Switzerland)
supplemented with 10% Fetal Calf Serum (FCS; Ser-
omed, Fakola, Basel, Switzerland) and antibiotics on
collagen type-I (Serva, Wallisellen, Switzerland) coated
ﬂasks. DHD/K12/TRs (referred to as REGb), a gener-
ous gift from Prof. F. Martin (INSERM, University of
Dijon, France), is a sub-clone of the chemically induced
rat colon carcinoma cell line DHD/K12. REGb cells
form regressive tumours when inoculated into syngeneic
BD-IX rats [16]. ReBeta cells are REGb cells which have
been transfected with the cDNA encoding for active
TGFb and selected in vivo (see below). REGb and
ReBeta cells were grown in 1:1 DMEM-HAM-F12 (Life
Technologies) supplemented with 10% FCS and anti-
biotics. To prepare cell culture conditioned media (CM),
cells were grown in culture media containing 10% FCS
until reaching 75% conﬂuence, then cultured for 48 h in
serum-free culture medium. The culture supernatants
were collected and spun for 10 min at 200 g and the
supernatants recovered. CCL-64 cells (a kind gift from
Dr K. Frei, Department of Neurosurgery, University
Hospital Zurich, Switzerland) is a mink-lung epithelial
cell line whose proliferation is inhibited by TGFb. CCL-
64 cells were grown in DMEM supplemented with 5%
FCS and 50 lM b-mercaptoethanol (Sigma, Buchs,
Switzerland).
Isolation and culture of bone marrow-derived
macrophages
Bone marrow-derived macrophages (BMDM) were
isolated from the femur and tibia of adult rats (OFA/
SPF; BRL, Fu¨llingsdorf, Switzerland). The bone-heads
were cut and the bone marrow was collected by rinsing
the bone cavity with 5 ml DMEM with a 25 G needle.
Resulting cell suspension was spun at 100 g for 5 min.
Cells were cultured in Sterilin petri dishes (Bibby Steri-
lin, Ostermundigen, Switzerland) in a diﬀerentiation
culture medium consisting of 50% DMEM 1 g/l glu-
cose, 30% culture supernatant of L929 mouse ﬁbro-
blasts and 20% horse serum (Life Technologies) and
antibiotics. After 7 days, cells were detached by incu-
bation for 30 min at 4 C and were further expanded in
the diﬀerentiation culture medium for 5 days. BMDM
were then washed with PBS and cultured in DMEM
supplemented with 10% FCS for 24 h, before perform-
ing experiments.
Transfection of REGb cells
Mutation of the Cys223 and Cys225 to Ser [17] induces
the production of TGFb1 peptides which do not asso-
ciate with the latency associated peptide resulting in the
secretion of constitutively biologically active TGFb1.
Five microgram of a PCRIII vector encoding mutated
porcine TGFb1, or a void vector as control, in 50 ll of
20 mM Hepes, pH 7.4 were adsorbed for 15 min at
room temperature onto the DOTAP Liposomal Trans-
fection Reagent (Roche Diagnostics, Rotkreuz, Swit-
zerland) at 30 lg/ml ﬁnal concentration under the
conditions described by the provider. Then 5 ml
DMEM were added and the resulting suspension was
added to half-conﬂuent REGb cells. The cells were
incubated for 4 h at 37 C, washed and grown in
DMEM containing 10% FCS for 5 days. Then trans-
fected cells were selected for 2 weeks in the presence of
800 lg/ml neomycin (Sigma), sub-cloned and grown in
DMEM-HAM-F12 (1:1) containing 10% FCS. The
production of active TGFb was measured using the
CCL-64 cell growth-inhibition assay (see below).
Animal experimentation
Two clones of TGFb-transfected REGb cells were se-
lected (see Table 1) depending on their level of secretion
of active TGFb (determined using the CCL-64 cell
growth-inhibition assay) and on their capacity to inhibit
iNOS activity in EC219 cells. Parental or transfected
REGb cells (transfected either with a void vector or the
vector containing the cDNA encoding active TGFb)
were injected subcutaneously (106 cells in 500 ll PBS per
rat) into syngeneic BD-IX rats (10 rats/group; brother–
sister mated since 1971 in the laboratory of Prof. F.
Martin). Tumour growth was evaluated weekly for
10 weeks by measuring width and length of the tumour
mass using calipers. The rats were then sacriﬁced. As
previously described, REGb cells always regressed when
injected under these conditions [16]. The only growing
tumor arising from the injection of active TGFb1-
transfected REGb cells was resected 10 weeks after
injection, enzymatically digested to yield single cell
suspension and expanded in vitro under the name
ReBeta cells. Their secretion of active TGFb was mea-
sured using the CCL-64 cell growth-inhibition assay and
ELISA for active TGFb.
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Inhibition of NO induction in EC219 cells
These experiments were performed essentially as previ-
ously described [14]. Brieﬂy, conﬂuent EC219 cells were
simultaneously exposed to 40 U/ml rat IFN-c (rIFN-c,
Immunogenetics, Antwerpen, Belgium) and 200 U/ml
murine TNF-a (mTNF-a, Roche), respectively and,
when indicated, the culture supernatants of untrans-
fected or transfected REGb cells for 24 h. Then NO
secretion in the EC219 cell culture medium was quan-
tiﬁed as nitrites using the Griess reagent as previously
described [14]. To verify the induction of iNOS by
cytokines in these cells, Western blotting experiments
were performed using with an anti-mouse iNOS anti-
body (Transduction Laboratories, Basel, Switzerland).
CCL-64 cell growth-inhibition assay for TGFb
quantiﬁcation
CCL-64 cells (5 104 per well) were incubated for 72 h
at 37 C in 96-well microtiter plates with serial dilutions
of unknown samples or recombinant human TGFb1
(rhTGFb; R&D Systems, Abingdon, UK) at increasing
concentrations (5 pg/ml to 1 ng/ml rhTGFb). Cell
proliferation was assessed by addition of 250 lg/ml
MTT [3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide] (Sigma) in DMEM during the last 2 h.
MTT crystals were dissolved with 0.04 N HCl in iso-
propanol and optical density was measured at 540 nm in
a multiwell microtiter plate reader (Labsystems iEMS
Reader MF). TGFb1 activity (pg/ml) in the samples was
determined by comparison with a rhTGFb standard
curve. Latent TGFb was activated by heating the sam-
ples at 95 C for 3 min, as previously described [14],
then active peptide determined using the CCL-64 cells.
Determination of TGFb protein level by ELISA
Secreted TGFb1 protein was measured in cell culture
conditioned media using paired antibodies cross-react-
ing with rat and porcine TGFb1 (R&D Systems)
according to the manufacturer’s instructions. Ninety-
six-well microtiter plates were coated with capture
antibody (MAB 240; 4 lg/ml in 100 ll PBS) and
unknown or rhTGFb1 (5 pg/ml to 5 ng/ml rhTGFb)
diluted in 20 mM Tris containing 150 mM NaCl, 0.1%
BSA and 0.05% Tween 20 (diluent solution) were added
and incubated for 2 h at room temperature, then bioti-
nylated detection antibody (BAF 240; 50 ng/ml in dil-
uent solution) was incubated for 2 h at room
temperature. Quantiﬁcation was done with peroxydase-
coupled Streptavidin (62.5 ng/ml in diluent solution,
Zymed Laboratories, San Francisco, CA), 0.006% H2O2
and 100 mg/ml tetramethylbenzidine (Sigma) in 0.05 M
phosphate–citrate buﬀer. The reaction was stopped with
0.5 M H2SO4 and optical density was measured at
450 nm using a reference ﬁlter at 620 nm in a multiwell
microtiter plate reader (Labsystems). Concentrations of
TGFb1 in samples were calculated by comparison with
a standard curve using rhTGFb.
NO and TGFb secretion by REGb and ReBeta cells
under cytokine stimulation
Cells were exposed to 40 U/ml rIFN-c, 200 U/ml
mTNF-a and 500 pg/ml rat IL-1b (rIL-1b, R&D system,
Abingdon, UK) for 24 h and NO or TGFb secretion in
the cell culture medium was quantiﬁed as nitrites using
the Griess reagent as previously described [14], or using
the CCL-64 cell growth inhibition assay, for NO or
TGFb, respectively.
Co-cultures of tumour cells with of endothelial cells
or macrophages
EC219 endothelial cells were plated alone or together
with either REGb or ReBeta tumour cells in 48-well
plates (2.5 104 EC219 cells and/or 5 104 tumour cells
per well). Cells were allowed to adhere overnight at
37 C and stimulated with 40 U/ml rIFN-c plus 200 U/
ml mTNF-a for 24 h in complete culture medium.
Culture supernatants were collected and nitrite concen-
trations determined using the Griess reagent [14]. Bone
marrow-derived macrophages were plated in 48-well
plates 24 h prior to addition of REGb or ReBeta tu-
mour cells (5 104 cells per well). After 24 h, cells were
activated with 40 U/ml rIFN-c plus 100 ng/ml Lipo-
polysaccharide (LPS; Sigma) for 24 h in the presence of
Table 1. TGFb secretion by colon carcinoma clones after transfection with constitutively-secreted active TGFb.
THFb-transfected REGb clones
3 11 14 16 18
CCL-64 cell growth inhibition ++ + + + +
iNOS inhibition in EC 219 cells
Conditioned medium + ) + ) +
Co-cultures + ND + ND +
REGb transfected clones were grown to 75% conﬂuence and culture medium was conditioned for 3 days in the absence of FCS. TGFb content in
the cell culture media was determined using either the CCL-64 growth inhibition assay, or the inhibition of NO secretion by EC219 cells or in co-
cultures of transfected cells with endothelial cells.
++: High levels of active TGFb; +: medium levels of active TGFb; ): below detection limits; ND not determined.
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10% FCS. Culture supernatants were collected and ni-
trite concentrations determined. Cultures of EC219,
REGb or ReBeta cells or macrophages alone were used
as controls.
Adhesion assay
EC219 cells in 48-well plates were either untreated or
treated for 48 h with either 40 U/ml rIFN-c plus 100 U/
ml mTNF-a or with 4 and 2 ng/ml or 400 pg/ml
rhTGFb. Cells were washed twice with DMEM without
FCS immediately prior to adhesion assay. REGb and
ReBeta tumour cells were labelled with 400 nCi/ml
[3H]thymidine (Amersham, Aylesbury, UK) for 10 h
and detached for 1 h at 37 C with EDTA (Versene, Life
Technologies). REGb or ReBeta tumour cells (105 cells
per well) were added to the EC219 cells in DMEM
without FCS. After 30 min at 37 C, non-adherent cells
were removed, collected and spun for 10 min at 200 g.
Adherent and non-adherent cells were dissolved over-
night in 0.1% SDS/0.1 M NaOH and radioactivity was
quantiﬁed in a b counter (LKB Rackbeta, Helsinki,
Finland).
Zymogram analysis of gelatinase activity
REGb-CM and ReBeta-CM supernatants were pre-
pared as described above and concentrated 30-fold by
centrifugation through a 5 kDa cut-oﬀ polymer mem-
brane (Millipore AG, Volketswil, Switzerland). Samples
(25 lg/lane) were resolved without prior denaturation
by electrophoresis in 10% SDS-polyacrylamide gel
containing 1 mg/ml gelatin (Merck, Switzerland). As
control, recombinant human MMP-2 (rhMMP-2; 4 ng/
lane; Oncogene Research Products, Luzern, Switzer-
land) was run in parallel. Following electrophoresis, gels
were washed free of SDS with 2.5% Triton X-100
(Fluka, Buchs, Switzerland) and incubated at 37 C for
24 h in 50 mM Tris–HCl pH 7.5 containing 200 mM
NaCl, 5 mM CaCl2 and 0.02% Brij-35 (Fluka) and
stained in with 0.05% Coomassie Brilliant Blue G-250
(Serva). MMP-2 activity was identiﬁed by its comigra-
tion with recombinant human MMP-2.
Statistical evaluation
Means, standard deviations (SD) and statistical signiﬁ-
cance were calculated using a paired Student’s t-test.
Results
Rat REGb colon carcinoma cells were transfected either
with the cDNA encoding constitutively-secreted active
TGFb1 or the empty vector as control. Transfected cells
grew at the same rate than parental cells. Following
2 week selection and sub-cloning, constitutive secretion
of active TGFb was measured in the culture superna-
tants of ﬁve diﬀerent clones using the CCL-64 cell
growth-inhibition assay, the inhibition of NO secretion
by endothelial EC219 cells or by co-cultures of trans-
fected REGb cells with endothelial cells (Table 1). Clone
3 produced very high levels of active TGFb, as assessed
by strong inhibition of CCL-64 cell growth and of NO
secretion by EC219 cells and were rejected for animal
experimentation to avoid risks of ﬁbrosis. Clones 11 and
16 produced low levels of active TGFb using the CCL-
64 cell growth-inhibition assay and their conditioned
media did not inhibit NO secretion by EC219 cells.
Clones 14 and 18 secreted levels of active TGFb that
were able to inhibit CCL-64 cell growth and NO secre-
tion by EC219 cells. Therefore these 2 clones were se-
lected for further animal experimentation. Either REGb
cells, REGb transfected with the empty vector (REGb
control), clone 14 or clone 18 were sub-cutaneously (s.c.)
injected into syngeneic rats. Injection of parental REGb
cells, conﬁrming previous results [16], or injection of
cells transfected with the empty vector, always resulted
in regressive tumours within 30 days. Out of 20 rats
injected with clone 14 or clone 18, only one tumour
developed spontaneously from clone 14 (Figure 1). This
tumour was resected, recultured under the name ReBeta
cells and characterised.
The secretion of total (latent + active) TGFb by
ReBeta and REGb cells was measured using an ELISA
(Table 2). As previously described [14], REGb cells se-
creted nearly detectable levels of active TGFb whereas
ReBeta cells secreted very high levels of TGFb. Active
TGFb secretion under cytokine stimulation was also
determined using the CCL-64-growth inhibition assay
(Figure 2). rIFN-c alone did not modulate TGFb
secretion either by REGb or ReBeta cells. rIFN-c in
combination with mTNF-a did not modulate TGFb
secretion by REGb cells, but increased TGFb secretion
by ReBeta cells (Figure 2). The secretion of NO by
REGb and ReBeta cells upon cytokine stimulation was
also evaluated. Addition of rIFN-c and mTNF-a
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Figure 1. In vivo progression of REGb cells and cell clones. REGb
cells (106 cells per rat), either parental (REGb parental), or
mock-transfected (REGb control), or transfected with constitutively-
secreted active TGFb (clone 14 and clone 18) were injected subcuta-
neously in syngeneic BD-IX rats (10 rats per group). Tumour
volume (in cm3) was evaluated weekly for 10 weeks.
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resulted in a slight increase of NO secretion only by
REGb cells, and the combination of rIFN-c, mTNF-a
and IL-1b resulted in a signiﬁcant increase of NO
secretion by both cell lines (P < 0.01) although the
cytokine-dependent increase of NO secreton by ReBeta
cells was signiﬁcantly lower than by REGb cells
(P < 0.01) (Figure 3). ReBeta and REGb cells secreted
equivalent amounts of matrix metalloproteinase
(MMP)-2, while secretion of MMP-9 was absent in both
cells (Figure 4).
The eﬀects of factors secreted by REGb and ReBeta
cells on the secretion of NO by EC219 endothelial cells
was evaluated. Treatment of EC219 endothelial cells
with 40 U/ml rIFN-c and 100 U/ml mTNF-a for 24 h
induced NO release (Figure 5), involving up-regulation
of iNOS expression as determined by mRNA level or
iNOS activity [14] or by Western Blot (Figure 5, insert).
Addition of ReBeta-cell conditioned medium (ReBeta-
CM) to EC219 cells simultaneously with cytokines
inhibited NO secretion whereas REGb-cell conditioned
medium (REGb-CM) did not (Figure 5). Then the role
of tumour cell-secretion of TGFb on rapid adhesion of
3H-Thymidine-labelled REGb or ReBeta cells to
monolayers of endothelial cells was evaluated. REGb
and ReBeta cells adhered similarly to EC219 cells
(Figure 6a). Treatment of endothelial cells with 40 U/ml
Table 2. ELISA determination of secretion of total (active + latent)
TGFb by REGb and ReBeta cells.
Conditioned media of tumor cells TGFb (pg/ml)
REGb-CM 44±10
ReBeta-CM 2926±50
Cells were grown to 75% conﬂuence and culture medium was condi-
tioned for 2 days in the absence of FCS. TGFb secretion in the cell
culture media was determined by a speciﬁc ELISA, and concentrations
of TGFb were calculated by comparison with rhTGFb as a standard.
Values are the means of triplicate determinations ±SD.
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Figure 2. Secretion of TGFb by cytokine-stimulated REGb and
ReBeta cells. REGb (light grey bars) or ReBeta (dark grey bars)
cells were grown to 60% conﬂuence, and either not stimulated (med-
ium) or stimulated with the indicated cytokines (40 U/ml rIFN-c,
100 U/ml mTNF-a) for 48 h and active TGFb secretion was quanti-
ﬁed using the CCL-64 growth inhibition assay. Data are means of
triplicate wells ±SD of one representative experiment out of 3.
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Figure 3. NO production by REGb and ReBeta cells under cytokine
stimulation. REGb (light grey bars) or ReBeta (dark grey bars) cells
were grown to 60% conﬂuence, and either not stimulated ()) or
stimulated (+) with the indicated cytokines (40 U/ml rIFN-c,
100 U/ml mTNF-a, 500 pg/ml rIL-1b) for 48 h and NO secretion
was determined. Statistical signiﬁcance was assessed using a two-
tailed paired Student’s t-test, *: P<0.05; **: P<0.01.
Figure 4. MMP-2 secretion by REGb and ReBeta cells. REGb and
ReBeta cells were grown to sub-conﬂuence and their culture media
was conditioned for 2 days in the absence of FCS, concentrated and
25 lg protein per lane were subjected to zymography. Recombinant
MMP-2 was used as a standard.
Figure 5. Eﬀects of soluble factors secreted by REGb or ReBeta
cells on NO production by endothelial cells. EC219 endothelial cells
were grown to 60% conﬂuence, and either not stimulated (medium,
light grey bar) or stimulated with 40 U/ml IFN-c and 100 U/ml
TNF-a, in the absence (medium, dark grey bar) or the presence of
either REGb (CM REGb, 50% ﬁnal concentration) or ReBeta con-
ditioned medium (CM ReBeta, 50% ﬁnal concentration) for 24 h
and NO secretion was determined. Data are means of triplicate wells
±SD of one representative experiment out of 3. Insert: The induc-
tion of iNOS protein by cytokine stimulation of EC219 cells was
veriﬁed by Western blotting.
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rIFN-c plus 100 U/ml mTNF-a or with increasing
concentrations of rhTGFb (400 pg/ml up to 4 ng/ml
rhTGFb) for 48 h prior to adhesion assay did not
modify their adhesive properties for either REGb (Fig-
ure 6b) or ReBeta cells (data not shown). In order to
eliminate endothelial cell line-speciﬁc eﬀects we per-
formed similar experiments using another rat endothe-
lial cell line, the CR3 cells [18], with similar information
(results not shown). Next, the eﬀect of direct contact
between REGb or ReBeta cells with endothelial cells on
the secretion of active or total TGFb was quantiﬁed in
the supernatant of co-cultures of EC219 cells with either
REGb or ReBeta cells. EC219 cells did not secrete
TGFb, no active TGFb and only low levels of latent
TGFb were detected in the supernatants of co-cultures
of EC219 with REGb cells, whereas the secretion of
active TGFb in co-cultures of ReBeta cells with EC219
cells was decreased (Figure 7).
Finally the eﬀect on NO secretion of direct contact
between REGb or ReBeta cells and EC219 endothelial
cells or bone marrow-derived macrophages was evalu-
ated. Co-culture of EC219 endothelial cells with either
REGb or ReBeta tumour cells did not modulate NO
production in the absence of added cytokines (results
not shown). However, NO production was inhibited
when cytokine-stimulated EC219 cells were in co-cul-
tures with either REGb or ReBeta cells (Figure 8). The
inhibition of cytokine-induced NO production by
EC219 cells can be reversed by addition of a blocking
anti-TGFb1 antibody [14] demonstrating the role of
TGFb in the inhibition of NO secretion by EC219 cells.
Addition of blocking anti-TGFb1 antibody to the co-
cultures did not restore NO secretion by cytokine-
stimulated EC219 cells (Figure 8, insert). Activation of
macrophages with rIFN-c and LPS resulted in the
secretion of large amounts of NO (Figure 9a). When
macrophages were in contact with REGb cells, NO
secretion was not modiﬁed, however in contact with
ReBeta cells, NO secretion was inhibited, suggesting
that the levels of active TGFb secretion by colon car-
cinoma cells is involved in the regulation of production
of NO by macrophage, but not by endothelial cells. Pre-
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Figure 6. Adhesion of REGb or ReBeta cells to endothelial cells. (a)
Unstimulated EC219 cells were exposed to 3H-Thymidine-labelled
REGb or ReBeta cells for 30 min, and adherent tumour cells were
quantiﬁed. (b) EC219 cells were stimulated with 40 U/ml IFN-c and
100 U/ml TNF-a, or with rhTGFb for 48 h, then exposed for
30 min to 3H-Thymidine-labelled REGb or ReBeta (results not
shown) cells, and adherent tumour cells were quantiﬁed. Results are
means ±SD of 3 independent experiments.
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Figure 7. TGFb secretion by co-cultures of endothelial cells and
REGb or ReBeta cells. EC219, REGb or ReBeta cells were grown
either alone (EC219, REGb, ReBeta) or in co-culture
(EC219 + REGb, EC219 + ReBeta) for 24 h, then stimulated with
40 U/ml IFN-c and 100 U/ml TNF-a for 24 h, and active (light grey
bars) and total (dark grey bars) TGFb secretion was quantiﬁed using
the CCL64 cell assay in the cell culture supernatants. Data are
means of triplicate wells ±SD of one representative experiment out
of 3.
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Figure 8. NO production in co-cultures of endothelial cells with ei-
ther REGb or ReBeta cells. EC219, REGb or ReBeta cells were
grown either alone (EC219, REGb, ReBeta) or in co-culture
(EC219 + REGb, EC219 + ReBeta) for 24 h, then either untreated
(light grey bars), or stimulated with 40 U/ml IFN-c and 100 U/ml
TNF-a (dark grey bars) for 24 h, and NO secretion was determined.
Statistical signiﬁcance was assessed using a two-tailed paired Stu-
dent’s t-test, *: P<0.05; **: P<0.01; ***: P<0.001. Results are
means of duplicate wells ±SD of one representative experiment out
of 3. Insert: In co-cultures of EC219 cells with either REGb (REGb)
or ReBeta (ReBeta) cells, addition of an anti-TGFb-blocking anti-
body did not restore NO secretion in response to cytokines. White
bars: cytokines; grey bars: cytokines + anti-TGFb antibody.
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treatment of macrophages for 24 h prior to rIFN-c and
LPS stimulation was not able to inhibit their NO
secretion (Figure 9b).
Discussion
TGFb family ligands signal through a common mech-
anism bringing together type I and type II Ser/Thr ki-
nase receptors, resulting in the phosporylation of type I
receptor by type II receptor and activation of intracel-
lular signalling pathways. Colon cancer cells predomi-
nantly produce TGFb in a latent form [19]. TGFb is
secreted as a latent complex of 290 kDa consisting of
bioactive TGFb (Mr 25 kDa), the latency-associated
peptide (LAP; Mr 75 kDa), and the latent TGFb bind-
ing protein 1 (LTBP1; Mr 190 kDa). LTBP1 is attached
to LAP by a disulﬁde bond, which is required for the
assembly and secretion of the latent TGFb complex and
prevents TGFb signalling [20]. Mutations of Cys223 and
Cys225 to Ser in the propeptide region of TGFb1 pre-
cursor [17] result in TGFb1 peptides which do not
associate to the LAP, and secretion of constitutively
biologically active TGFb1. TGFb has been proposed to
favour tumour progression in colon carcinoma but its
contribution has not been clearly established. TGFb is a
potent growth inhibitor for normal epithelial cells,
whereas in carcinoma cells, including colon cancer cells,
mutations in the genes encoding TGFb receptors fre-
quently inactivate signalling [21]. TGFb produced by
tumour cells also exerts a paracrine eﬀect on tumour
stroma [12]. Therefore in the early stages of cancer
TGFb is anti-tumoural, inhibiting proliferation of tu-
mour cells, whereas in later stages, TGFb rather pro-
motes cancer progression by acting as a permissive
factors for stromal cells to inhibit host immune sur-
veillance, and stimulate invasion, angiogenesis and
metastasis.
In the present experiments, in order to address the
role of the interplay between TGFb and NO in cancer
progression, we tested the hypothesis that the levels of
active-TGFb secretion by tumour cells is involved in
stromal cell functions, particularly in modulating tu-
mour cell interaction with endothelial cells and macro-
phages. To evaluate this hypothesis, we decided to
perform in vivo selection of REGb cells engineered to
secrete high levels of active TGFb, then to perform in
vitro studies, comparing REGb cells with active-TGFb-
transfected REGb cells which had demonstrated the
capacity for in vivo progression. Therefore REGb cells
were transfected with a cDNA encoding constitutively-
secreted active TGFb and these modiﬁed REGb cells
were injected in syngeneic rats. The in vivo progression
of tumour cells was evaluated and the interaction in vitro
of a progressive tumour, ReBeta cells, with endothelial
cells and macrophages was analysed in relation with
tumour cell-dependent secretion of TGFb and regula-
tion of NO production.
Our results demonstrated that the secretion by colon
carcinoma cells of high levels of active TGFb is not
suﬃcient for a high incidence of tumour progression
since out of 20 animals only one harboured a progres-
sive tumour, which after resection still secreted high
levels of TGFb. With the present approach we cannot
ascertain whether the expression of the transfected
peptide was maintained in the 19 animals which did not
develop tumours. The autocrine secretion of high levels
of active TGFb did not inhibit growth of TGFb-trans-
fected REGb cells, suggesting the loss of responsiveness
of these cells for this eﬀect of TGFb. After in vivo pro-
gression of TGFb-transfected REGb cells, cytokine
activation further increased their TGFb secretion, but
decreased their production of NO compared to REGb
cells. Levels of active TGFb secretion in this model did
not modify MMP-2 production, therefore excluding a
role for TGFb in promoting cancer progression via this
pathway, which is in accordance with the information
that tumour-associated ﬁbroblasts are the main source
of MMPs in tumours. NO has been shown to increase
tumour cells adhesion to cytokine-stimulated endothe-
lial cells [3], or to reduce tumour cell adhesion to post-
capillary venules [6]. The cytokines TNF-a and IFN-c
are known to increase adhesive properties of the endo-
thelium. Treatment of endothelial cells with re-
combinant TGFb or exposure of endothelial cells to
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Figure 9. NO production by co-cultures of macrophages with either
REGb or ReBeta cells. (a) Macrophages (mF) were grown alone, or
with either REGb or ReBeta (mF + REGb, mF + ReBeta) cells
for 24 h, then either untreated (light grey bars) or treated with 40 U/
ml IFN-c and 100 ng/ml LPS for 24 h, and NO concentrations were
measured in culture supernatants. Results are means ±SD of tripli-
cate wells of one representative experiment out of 3. Statistical sig-
niﬁcance was assessed using a two-tailed paired Student’s t-test,
*: P<0.05; **: P<0.01; ***: P<0.001. (b) Macrophages were ei-
ther untreated or pre-treated for 24 h with 1.5 ng/ml rhTGFb
(TGBb bars), then exposed either to culture medium (–, TGFb) or
stimulated with 40 U/ml IFN-c and 100 ng/ml LPS for 24 h (I + L,
TGFb/I + L), and NO concentrations were measured in culture su-
pernatants. Results are means ±SD of triplicate wells of one repre-
sentative experiment out of 3.
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melanoma cells secreting latent TGFb enhanced adhe-
sion of tumour cells to endothelial cells [22]. Our present
results demonstrated that the levels of active TGFb
secretion by colon carcinoma cells and the modulation
by TGFb of NO secretion by endothelial cells did not
modify adhesive properties between endothelial and
tumour cells, irrespective of cytokine stimulation of
endothelial cells. In our model, the absence of modula-
tion of tumour cells adhesion to cytokine-activated
endothelial cells suggested that the interactions of colon
carcinoma cells with endothelial cells are not based on
the modulation by cytokines of the adhesive properties
of adhesion molecules. In agreement with these results
we have previously shown in a breast cancer model of
lung metastasis that NO did not inﬂuence the early
stages of tumour metastasis and the interaction of
invading tumour cells with pulmonary endothelial cells,
but that the cellular origin of NO was critical to the
metastatic process [23]. Progressive colon carcinoma
cells (PROb cells) secreting active TGFb had the ability
to inhibit cytokine-induced NO production in EC219
endothelial cells and microglial cells while a regressive
clone (REGb cells) isolated from the same carcinoma
but secreting only latent TGFb did not display these
properties [14]. In PROb cells, regulation of NO secre-
tion by TGFb was an intracrine process, whereas exo-
geneously added TGFb was ineﬀective [24].
The activation of latent TGFb has been shown to be
mediated by direct contact between endothelial and
smooth muscle cells [25]. In co-cultures of EC219 with
REGb or ReBeta cells, both cell lines behaved compa-
rably, suggesting that latent TGFb could be activated
through intercellular mechanisms. Tumour-cell derived
IFN-b stimulates NO production by host cells, including
macrophages, and suppresses tumour progression [26].
TGFb is able to block cytokine-mediated activation of
macrophages and their NO secretion [27, 28] and is in-
volved in the suppression of local immune response and
NO-mediated macrophage cytotoxicity. Therefore tu-
mour progression was inversely related to NO secretion
by macrophages [29]. In our model, the level of TGFb
secretion, and the resulting modulation of NO secretion
by macrophages was important in the mechanisms of
interaction of colon carcinoma cells with macrophages.
The decreased secretion of NO could be due to the
blockade of macrophage activation by high levels of
active TGFb secreted by ReBeta cells, but not REGb
cells. However, pre-exposure of macrophages to
rhTGFb before rIFN-c and LPS stimulation failed to
mimic this inhibitory eﬀect. These results suggest that
continuous presence of high levels of TGFb, as achieved
in co-culture of macrophages with ReBeta cells, is nec-
essary for this eﬀect, or that direct contact, or alterna-
tively that other molecules, are involved.
In conclusion, our study demonstrates that the
secretion of high levels of active TGFb is not suﬃcient
to generally allow colon carcinoma cells to progress in
vivo. These results also demonstrate that the adhesion of
tumour cells to endothelial cells does not depend on the
level of secretion of active TGFb by tumour cells, sug-
gesting that the NO-modulated adhesion of tumour cells
to the endothelium is not a limiting factor for progres-
sion. The inhibition of NO production in macrophages
depended on the level of active TGFb secreted by tu-
mour cells, indicating that immunomodulation of the
host defence mechanisms by high TGFb and the
resulting modulation of the TGFb–NO axis may be re-
lated to tumour progression.
Acknowledgements
The authors thank the Swiss League against Cancer
(Grants SKL 353-9-1996, KFS 947-09-1999 and KPS
1070-09-2000), the program ‘‘Co-tutelle de the`se’’ of
the University of Lausanne and EPHE, the Pro-
gramme d’Actions Inte´gre´es Germaine de Stael and
the Swiss Society for Multiple Sclerosis, for supporting
these researches.
References
1. Leu RW, Leu NR, Shannon BJ et al. IFN-c diﬀerentially
modulates the susceptibility of L1210 and P815 tumor targets for
macrophage-mediated cytotoxicity. Role of macrophage-target
interaction coupled to nitric oxide generation, but independent of
tumor necrosis factor production. J Immunol 1999; 147: 1816–22.
2. Li LM, Kilbourn RG, Adams J et al. Role of nitric oxide in lysis
of tumor cells by cytokine-activated endothelial cells. Cancer Res
1991; 51: 2531–5.
3. Vidal MJ, Zocchi MR, Poggi A et al. Involvement of nitric oxide
in tumor cell adhesion to cytokine-activated endothelial cells.
J Cardiovasc Pharmacol 1992; 20: S155–9.
4. Curley SA, Roh MS, Feig B et al. Mechanisms of Kupﬀer cell
cytotoxicity in vitro against the syngeneic murine colon adeno-
carcinoma line MCA26. J Leukoc Biol 1993; 53: 715–21.
5. Dong Z, Staroselsky AH, Qi X et al. Inverse correlation between
expression of inducible nitric oxide synthase activity and
production of metastasis in K-1735 murine melanoma cells.
Cancer Res 1994; 54: 789–93.
6. Kong L, Dunn GD, Keefer LK et al. Nitric oxide reduces tumor
cell adhesion to isolated rat postcapillary venules. Clin Exp
Metastasis 1996; 14: 335–43.
7. Murata J, Ricciardi-Castagnoli P, Dessous L’Eglise Mange P et
al. Microglial cells induce cytotoxic eﬀects toward colon carci-
noma cells: Measurement of tumor cytotoxicity with a gamma-
glutamyl transpeptidase assay. Int J Cancer 1997; 70: 169–74.
8. Wink DA, Vodovotz Y, Laval J et al. The multifaceted roles of
nitric oxide in cancer. Carcinogenesis 1998; 19: 711–21.
9. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology,
pathology and pharmacology. Pharmacol Rev 1991; 43: 109–42.
10. Benson JR. Role of transforming growth factor beta in breast
carcinigenesis. Lancet Oncol 2004; 5: 229–39.
11. Welch DR, Fabra A, Nakajima M. Transforming growth factor-
b stimulates mammary adenocarcinoma cell invasion and meta-
static potential. Proc Natl Acad Sci USA 1990; 87: 7678–82.
12. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA,
Derynck R. Increased transforming growth factor b expression
inhibits cell proliferation in vitro, yet increases tumorigenicity and
tumor growth of meth A sarcoma cells. Cancer Res 1993; 53:
4391–8.
13. Shimizu S, Nishikawa Y, Kuroda K et al. Involvement of
transforming growth factor beta 1 in autocrine enhancement of
gelatinase B secretion by murine metastatic colon carcinoma cells.
Cancer Res 1996; 56: 3366–70.
348 S. Lohm et al.
14. Murata J, Betz Corradin S, Felley-Bosco E et al. Involvement of a
transforming-growth-factor-b-like molecule in tumor-cell-derived
inhibition of nitric oxide synthesis in cerebral endothelial cells. Int
J Cancer 1995; 62: 743–8.
15. Juillerat-Jeanneret L,AguzziA,WiestlerODet al.Dexamethasone
selectively regulates the activity of enzymatic markers of cerebral
endothelial cell lines. In Vitro Cell Dev Biol 1992; 28A: 537–43.
16. Caignard A, Martin MF, Martin F. Interaction between two
cellular sub-populations of a rat colonic carcinoma when inoc-
ulated to the syngeneic host. Int J Cancer 1985; 36: 273–9.
17. Brunner AM, Marquardt H, Malacko AR et al. Site-directed
mutagenesis of cysteine residues in the pro region of transforming
growth factor b1 precursor. J Biol Chem 1989; 264: 13660–4.
18. Lechardeur D, Schwartz B, Paulin D et al. Induction of blood–
brain barrier diﬀerentiation in a rat brain-derived endothelial cell
line. Exp Cell Res 1995; 220: 161–70.
19. Coﬀey RJ, Shipley GD, Moses H. Production of transforming
growth factors by human colon cancer lines. Cancer Res 1986; 46:
1164–9.
20. Derynck R, Akhurst RJ, Balmain A. TGF-b signaling in tumor
suppression and cancer progression. Nat Genet 2001; 29: 117–29.
21. Massague´ J, Blain SW, Lo RS. TGFb signaling in growth
control, cancer and heritable disorders. Cell 2000; 103: 295–309.
22. Teti A, De Giorgi A, Spinella MT et al. Transforming growth
factor-b enhances adhesion of melanoma cells to the endothelium
in vitro. Int J Cancer 1997; 72: 1013–20.
23. Gauthier N, Lohm S, Touzery C et al. Tumor-derived and host-
derived nitric oxide diﬀerently regulate breast carcinoma metas-
tasis to the lungs. Carcinogenesis 2004; 25: 1559–65.
24. Lagadec P, Raynal S, Lieubeau B et al. Evidence for control of
nitric oxide synthesis by intracellular transforming growth factor-
b1 in tumor cells. Implications for tumor development. J Am
Pathol 1999; 154: 1867–76.
25. Sato Y, Okada F, Abe M et al. The mechanism for the
activation of latent TGF- beta during co-culture of endothelial
cells and smooth muscle cells: Cell-type speciﬁc targeting of
latent TGF-beta to smooth muscle cells. J Cell Biol 1993; 123:
1249–54.
26. Wei D, Richardson EL, Zhu K et al. Direct demonstartion of
negative regulation of tumor growth and metastasis by host
inducible nitric oxide synthase. Cancer Res 2003; 63: 3855–9.
27. Corradin SB, Buchmuller-Rouiller Y, Smith J et al. Trans-
forming growth factor beta 1 regulation of macrophage
activation depends on triggering stimulus. J Leukoc Biol
1993; 54: 423–9.
28. Erwig LP, Kluth DC, Walsh GM et al. Initial cytokine exposure
determines function of macrophages and renders them unrespon-
sive to other cytokines. J Immunol 1998; 161: 1983–8.
29. Farias-Eisner R, Sherman MP, Aeberhald E et al. Nitric oxide is
an important mediator for tumoricidal activity in vivo. Proc Nat
Acad Sci USA 1994; 91: 9407–11.
TGFb and nitric oxide in colon cancer 349
